What Transformation Has the Acute Myeloid Leukemia Market Undergone?
The acute myeloid leukemia market has seen considerable growth due to a variety of factors.
• Having shown robust growth in the past few years, the acute myeloid leukemia market size is set to expand from $3.5 billion in 2024 to $3.79 billion in 2025, representing a compound annual growth rate (CAGR) of 8.2%.
The upward surge throughout this historical period can be credited to factors such as the increase in aging population, environmental influences, genetic susceptibility, the scarcity of treatment alternatives, as well as medical advancements.
What is the Forecasted Market Size and CAGR for the Acute Myeloid Leukemia Market?
The acute myeloid leukemia market is expected to maintain its strong growth trajectory in upcoming years.
• The market size for acute myeloid leukemia is projected to experience significant expansion in the upcoming years, with an estimated valuation of $5.02 billion by 2029 and a compound annual growth rate (CAGR) of 7.3%.
The anticipated growth during the forecast period is largely attributable to enhancements in targeted treatments, the progression of immunotherapies, precision medicine methodologies, increased cognizance and early diagnosis, as well as collective research initiatives. Key trends throughout this forecast period encompass an emphasis on monitoring minimal residual disease, the incorporation of artificial intelligence (AI) in aiding treatment decisions, a focus on supportive care and interventions for quality of life, combined research initiatives and clinical trials, along with programs aimed at patient advocacy and empowerment.
What Are The Core Factors Supporting Growth In Acute Myeloid Leukemia Market?
The surge in the aging population along with escalating unresolved medical needs is anticipated to drive the expansion of the acute myeloid leukemia market in the coming years. The term 'geriatric population and growing unmet healthcare needs' is typically used to describe individuals aged 65 and above who are tackling health problems like acute myeloid leukemia. For instance, data from the American Cancer Society USA, a nationwide voluntary health organization, reveals that in 2022, AML was mainly diagnosed in senior citizens, with an average age of diagnosis being 68, yet the survival rate for these elderly patients remained notably low. The illness had affected approximately 60,650 individuals and resulted in 24,000 fatalities in 2022. Hence, the rising elderly population and escalating unattended healthcare needs are propelling the growth of the gelatin market.
What Are The Principal Market Segments In The Global Acute Myeloid Leukemia Healthcare Industry?
The acute myeloid leukemia market covered in this report is segmented –
1) By Treatment Type: Chemotherapy, Radiation therapy, Stem Cell Transplant, Targeted Therapy
2) By Chemotherapy: Cytarabine, Anthracycline Drugs, Alkylating Agents, Anti-metabolites, Tyrosine Kinase Inhibitors, Hormonal Therapy
3) By Regimen: DC Regimen, AVD Regimen, VCD Regimen
4) By End-User: Hospital, Retails Drug Stores, Ambulatory Care Centers, Clinics
Subsegments:
1) By Chemotherapy: Induction Chemotherapy, Consolidation Chemotherapy
2) By Radiation Therapy: Total Body Irradiation, Localized Radiation Therapy
3) By Stem Cell Transplant: Autologous Stem Cell Transplant, Allogeneic Stem Cell Transplant
4) By Targeted Therapy: Tyrosine Kinase Inhibitors (TKIs), Monoclonal Antibodies, Other Targeted Agents
Pre-Book The Acute Myeloid Leukemia Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Emerging Market Trends Are Altering The Acute Myeloid Leukemia
The trend of escalating investments in research and development by pharmaceutical companies is increasingly prominent in the acute myeloid leukemia market. This R&D approach aims to create innovative and advanced products and services to meet the demands of drug development. For instance, a study named ‘Daunorubicin or Idarubicin with Cytarabine Plus Quizartinib vs. Physician's Choice in Newly Diagnosed FLT3-ITD+ AML (Q-SOC)’ was reported, as per the National Library of Medicine, a medical library based in the U.S. The study is currently in its third phase of clinical trials, which began in November 2021, with an expected completion in March 2025.
Who Are the Key Players in the Acute Myeloid Leukemia Market?
Major companies operating in the acute myeloid leukemia market include:
• Pfizer Inc.
• F. Hoffmann-La Roche AG
• AbbVie Inc.
• Novartis AG
• Sanofi-Aventis (Genzyme Corporation)
• Bristol Myers Squibb Company
• GlaxoSmithKline plc
• Takeda Pharmaceuticals
• Amgen Inc.
• Otsuka Holdings Co. Ltd.
• Teva Pharmaceutical
• Celgene Corporation
• Astellas Pharma
• Servier Pharmaceuticals
• CSPC Pharmaceutical Group
• Genmab AS
• Zhejiang Medicine Co. Ltd.
• Syndax Pharmaceuticals Inc.
• Astex Pharmaceuticals Inc.
• MEI Pharma Inc.
• SELLAS Life Sciences Group
• Ambit Biosciences Corporation
• Agios Pharmaceuticals Inc.
• Neomed Management AS
• Oncolyze Inc.
• TC BioPharm
• VERASTEM INC.
• Mirati Therapeutics Inc.
• Sunshine Lake Pharma
• Sunesis Pharmaceuticals Inc.
What are the Regional Insights into the Acute Myeloid Leukemia Market?
North America was the largest region in the acute myeloid leukemia market in 2024. The regions covered in the acute myeloid leukemia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
